Skip to main content

Table 3 Organ-specific tumor response (n = 140)

From: Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Sites

CR

PR

SD

ORR

DCR

Liver (n = 129)

9

7.0%

16

12.4%

40

31.0%

19.4%

50.4%

Thrombosis (n = 81)

2

2.5%

4

4.9%

25

30.9%

7.4%

38.3%

Lung (n = 15)

2

13.3%

3

20.0%

3

20.0%

33.3%

53.3%

Lymph node (n = 7)

0

0.0%

1

14.3%

1

14.3%

14.3%

28.6%

Peritoneum (n = 5)

1

20.0%

1

20.0%

0

0.0%

40.0%

40.0%

Bone (n = 5)

0

0.0%

0

0.0%

1

20.0%

0.0%

20.0%

Adrenal gland (n = 4)

0

0.0%

2

50.0%

0

0.0%

50.0%

50.0%

  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate